Cerus Corporation Announces Symposium and Abstracts at the 33rd Regional ISBT Congress
15 Giugno 2023 - 2:30PM
Business Wire
Symposium and Abstracts Highlight Data from
Studies of INTERCEPT Platelets and Plasma as well as Developmental
Programs
Cerus Corporation (Nasdaq:CERS) today announced a selection of
abstracts and a lunch symposium at the 33rd Regional International
Society of Blood Transfusion (ISBT) Congress, taking place in
Gothenburg, Sweden, from June 17 through June 21. Transfusion
medicine experts and professionals from around the world attend the
ISBT Congress. This year marks the first time the conference has
taken place in person since 2019.
The following is a select list of presentations and abstracts of
interest for Cerus. All presentation times are listed in Central
European Time (CET).
Oral Presentations
- Monday, June 19, 2023 – 12:30 p.m. – Cerus Lunch
Symposium:
- Implementation of pathogen reduced products: considerations
from the Canadian perspective and first experiences.
- Improving patient safety through pathogen inactivation: the
Stanford experience.
- Strategies to reduce transfusion-transmitted bacterial
infections: screening, pathogen inactivation, and cold stored
platelets components.
- Wednesday, June 21, 2023 – 9:15 a.m.– In Vitro Biochemical
and Functional Comparison of Amotosalen-UVA-Treated Buffy-Coat
Platelet Concentrates Stored in PAS-C Or PAS-E Additive Solution up
to 7 Days
Poster Presentations
Held between Sunday, June 18 and Tuesday, June 20, 2023
- Platelet Safety Measures in Sweden: An Assessment of Current
Practices and Comparison with International Practices
- In Vitro Biochemical and Functional Characteristics of Stored
(Double-Dose) Buffy-Coat Platelet Concentrates Treated With
Amotosalen and a Prototype UVA Light-Emitting Diode
Illuminator
- Evaluation of the In Vitro Properties Out to 7 Days of Buffy
Coat Platelets Stored in PAS C Or PAS E and Treated With Amotosalen
and a Prototype LED UVA Light Source
- Initial Experience of Switching Pathogen Inactivation System
With Extended Platelet Shelf Life
- Transfusion of Amotosalen-UVA Pathogen Reduced Platelet
Components to Mature and Premature Neonatal Infants
- Amotosalen/UVA Light Pathogen Reduced Plasma from Previously
Quarantined Units Stored for Two Years
- A Pilot Study Tracking Pathogen Reduced RBCs In Vivo Using
Surface Acridine and Biotin Flow Cytometric Markers
The full program of Cerus-related abstracts can be found at the
following link:
https://interceptbloodsystem.com/sites/default/files/resources/2023_isbt_abstractbook_final.pdf.
Cerus representatives will be in the exhibition area at booth
#2716.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Headquartered in Concord, California, the company
develops and supplies vital technologies and pathogen-protected
blood components to blood centers, hospitals, and ultimately
patients who rely on safe blood. The INTERCEPT Blood System for
platelets and plasma is available globally and remains the only
pathogen reduction system with both CE Mark and FDA approval for
these two blood components. The INTERCEPT red blood cell system is
under regulatory review in Europe, and in late-stage clinical
development in the US. Also in the US, the INTERCEPT Blood System
for Cryoprecipitation is approved for the production of Pathogen
Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to
as INTERCEPT Fibrinogen Complex), a therapeutic product for the
treatment and control of bleeding, including massive hemorrhage,
associated with fibrinogen deficiency. For more information about
Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230615560378/en/
Jessica Hanover – Vice President, Corporate Affairs Cerus
Corporation 925-288-6137
Grafico Azioni Cerus (NASDAQ:CERS)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Cerus (NASDAQ:CERS)
Storico
Da Ott 2023 a Ott 2024